170 related articles for article (PubMed ID: 35852273)
1. The 13.5-mg, 19.5-mg, and 52-mg Levonorgestrel-Releasing Intrauterine Systems and Risk of Ectopic Pregnancy.
Elgemark K; Graner S; McTaggart J; Ramirez Löfström J; Sörensen D; Envall N; Kopp Kallner H
Obstet Gynecol; 2022 Aug; 140(2):227-233. PubMed ID: 35852273
[TBL] [Abstract][Full Text] [Related]
2. Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy.
Graner S; Mc Taggart J; Nordström F; Melander E; Widenberg J; Kopp Kallner H
Acta Obstet Gynecol Scand; 2019 Jul; 98(7):937-943. PubMed ID: 30737766
[TBL] [Abstract][Full Text] [Related]
3. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
[TBL] [Abstract][Full Text] [Related]
4. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
Luukkainen T; Toivonen J
Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
[TBL] [Abstract][Full Text] [Related]
5. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
[TBL] [Abstract][Full Text] [Related]
6. A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents.
Gemzell-Danielsson K; Buhling KJ; Dermout SM; Lukkari-Lax E; Montegriffo E; Apter D
Contraception; 2016 Jun; 93(6):507-12. PubMed ID: 26872720
[TBL] [Abstract][Full Text] [Related]
7. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
Todd CS; Jones HE; Langwenya N; Hoover DR; Chen PL; Petro G; Myer L
PLoS Med; 2020 May; 17(5):e1003110. PubMed ID: 32442189
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial.
Gemzell-Danielsson K; Apter D; Hauck B; Schmelter T; Rybowski S; Rosen K; Nelson A
PLoS One; 2015; 10(9):e0135309. PubMed ID: 26378938
[TBL] [Abstract][Full Text] [Related]
9. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
French R; Van Vliet H; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Helmerhorst F; Guillebaud J
Cochrane Database Syst Rev; 2004; 2004(3):CD001776. PubMed ID: 15266453
[TBL] [Abstract][Full Text] [Related]
10. Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.
Nelson AL
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):833-842. PubMed ID: 28617060
[TBL] [Abstract][Full Text] [Related]
11. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
12. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.
Papaikonomou K; Kopp Kallner H; Söderdahl F; Gemzell-Danielsson K
Hum Reprod; 2018 Nov; 33(11):2002-2009. PubMed ID: 30295731
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy during the use of levonorgestrel intrauterine system.
Backman T; Rauramo I; Huhtala S; Koskenvuo M
Am J Obstet Gynecol; 2004 Jan; 190(1):50-4. PubMed ID: 14749634
[TBL] [Abstract][Full Text] [Related]
14. Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception.
Bilgehan F; Dilbaz B; Karadag B; Deveci CD
J Obstet Gynaecol Res; 2015 Sep; 41(9):1426-32. PubMed ID: 26180028
[TBL] [Abstract][Full Text] [Related]
15. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
16. Immediate versus delayed initiation of the levonorgestrel-releasing intrauterine system following medical termination of pregnancy - 1 year continuation rates: a randomised controlled trial.
Korjamo R; Mentula M; Heikinheimo O
BJOG; 2017 Dec; 124(13):1957-1964. PubMed ID: 28650566
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use.
Gemzell-Danielsson K; Apter D; Dermout S; Faustmann T; Rosen K; Schmelter T; Merz M; Nelson A
Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():22-28. PubMed ID: 27930941
[TBL] [Abstract][Full Text] [Related]
18. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
19. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
20. LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years.
Nelson AL
Expert Opin Drug Deliv; 2017 Sep; 14(9):1131-1140. PubMed ID: 28696796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]